Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • ID: 3978518
  • Report
  • Region: Global
  • 61 Pages
  • GBI Research
1 of 4
Asthma Therapeutics Market to Diversify in Order to Help Underserved Patients and Generate strong Revenues
Asthma is a chronic condition affecting the respiratory system, with disease occurrence linked to both genetic and environmental factors. It has significant global incidence and there is currently no cure. Pharmacotherapeutic intervention aims to provide patients with an increased level of disease control and reduce the severity of symptoms, and a number of inhalational therapeutic options are available.

While the asthma market is dominated almost exclusively by small molecules, which account for 99.6% of available products, the asthma pipeline consists of 13% general biologics and 12% monoclonal Antibodies (mAb). There are 173 small molecules, equating to 65%. The rise in mAb development is possibly due to the success of Xolair (omalizumab), one of the few currently marketed mAb asthma therapeutics, which reached blockbuster status in 2014. Xolair is a recombinant humanized anti-IgE, and was the first humanized therapeutic mAb to be indicated for asthma.

Over the past decade, the pharmaceutical industry has witnessed a profound change in the technological, clinical and commercial landscape across several therapeutic areas and indications. These changes include a remarkable transition towards biologic products in R&D, on an unprecedented scale. This has been facilitated by significant advances in recombinant DNA technologies, which accelerated the capabilities in the design of biologic therapeutics and substantially improved the yields in the manufacturing processes for biologics, improving productivity and profitability. As a result of these developments, the number and diversity of molecule types in developmental pipelines have increased substantially, and are expected to continue to grow in the years to come, particularly mAbs, proteins, peptides and vaccines.

The prevalence of asthma in the US increased from 7.3% in 2001 to 8.4% in 2010 (CDC, 2012). Data derived from the same study also confirmed the prevalence of asthma to be higher among children than adults, and higher among multiple-race, black, and American Indian or Alaska Native people than white people, for the 2008-2010 period.

The report “Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation” provides the following:
  • Analysis of innovation in the asthma market in the context of the overall pipeline and current market landscape - also includes analysis of the deals landscape surrounding first-in-class products in asthma, and highlights opportunities for in-licensing.
  • A brief introduction to asthma, including symptoms, pathophysiology, and an overview of pharmacotherapy.
  • The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline.
  • Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
  • Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
  • Assessment of the licensing and co-development deal landscape for asthma therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

1 Table of Contents

2 Executive Summary
2.1 Biologics and mAbs Growing in Prominence in Asthma Treatment
2.2 Market Landscape to Grow in Diversity over Coming Years
2.3 Cytokine and Kinase Targeted Small Molecules and mAbs Dominate First-in-Class Innovation
2.4 Deals Landscape Offers Significant Investment Opportunities for First-in-Class Products

3 The Case for Innovation in the Asthma Market
3.1 Growing Number of Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Developments Remain Attractive
3.4 Changes in Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Indications
3.5 Sustained Innovation
3.6 Research Report Guidance

4 Clinical and Commercial Landscape
4.1 Disease Overview
4.2 Epidemiology
4.3 Etiology
4.4 Pathophysiology
4.5 Disease Symptoms
4.6 Diagnosis
4.6.1 Disease Prognosis
4.6.2 Assessment of Disease Severity
4.7 Treatment
4.7.1 Quick-Relief Medication
4.7.2 ICSs for the Maintenance Treatment of Asthma
4.7.3 ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma
4.7.4 Add-on Therapies to ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma
4.7.5 Treatment Algorithm
4.8 Overview of Marketed Products
4.9 Current Unmet Need in the Asthma Market

5 Assessment of Pipeline Product Innovation
5.1 Asthma Pipeline by Molecule Type, Stage of Development and Molecular Target
5.2 Comparative Distribution of Programs between the Asthma Market and Pipeline by Molecular Target
5.3 First-in-Class Pipeline Programs Targeting Novel Molecular Targets

6 Signaling Network and Innovation Alignment
6.1 Complexity of Signaling Networks in Asthma
6.2 First-in-Class Matrix Assessment

7 First-in-Class Target Evaluation
7.1 Pipeline Programs Targeting Calcium Release Activated Calcium Channel Protein 1
7.1.1 Overview of Pipeline Programs Targeting Calcium Release Activated Calcium Channel Protein 1
7.2 Pipeline Programs Targeting CXC Chemokine Receptors
7.2.1 Overview of Pipeline Programs Targeting CXC Chemokine Receptors
7.3 Pipeline Programs Targeting Spleen Tyrosine Kinase
7.3.1 Overview of Pipeline Programs Targeting Spleen Tyrosine Kinase
7.4 Pipeline Programs Targeting Compliment Component 5a Receptor 1
7.4.1 Overview of Pipeline Programs Targeting Compliment Component 5a Receptor 1
7.5 Pipeline Programs Targeting Interleukin-33
7.5.1 Overview of Pipeline Programs Targeting Interleukin-33
7.6 Pipeline Programs Targeting CC Chemokine Receptor Type 3
7.6.1 Overview of Pipeline Programs Targeting CC Chemokine Receptor Type 3
7.7 Pipeline Programs Targeting Antigen Presenting Glycoprotein CD1d
7.7.1 Overview of Pipeline Programs Targeting Antigen Presenting Glycoprotein CD1d
7.8 Pipeline Programs Targeting Interleukin 4 Receptor Subunit Alpha
7.8.1 Overview of Pipeline Programs Targeting Interleukin 4 Receptor Subunit Alpha
7.9 Conclusion

8 Deals and Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Asthma Deals Landscape
8.3 Licensing Deals
8.3.1 Molecule Type
8.3.2 Molecular Target
8.4 Co-development Deals
8.4.1 Molecule Type
8.4.2 Molecular Target
8.5 Pipeline Products without Prior Licensing or Co-Development Deal Involvement

9 Appendix
9.1 References
9.2 Abbreviations
9.3 Primary Research

List of Tables

Table 1: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children Aged 0-4
Table 2: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children Aged 5-11
Table 3: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Youths =12 Years of Age and Adults
Table 4: Asthma Therapeutics Market, Global, Management of Chronic Asthma
Table 5: Asthma Therapeutics Market, Global, Management of Chronic Asthma
Table 6: Asthma Therapeutics Market, Global, Management of Acute Asthma
Table 7: Asthma Therapeutics Market, Global, Data for Calcium Release Activated Calcium Channel Protein 1 as a Molecular Target
Table 8: Asthma Therapeutics Market, Global, Data for CXC Chemokine Receptors as Molecular Targets, 2016
Table 9: Asthma Therapeutics Market, Global, Data for Spleen Tyrosine Kinase as a Molecular Target, 2016
Table 10: Asthma Therapeutics Market, Global, Data for Compliment Component 5a Receptor 1 as a Molecular Target, 2016
Table 11: Asthma Therapeutics Market, Global, Data for Interleukin-33 as a Molecular Target, 2016
Table 12: Asthma Therapeutics Market, Global, Data for CC Chemokine Receptor Type-3 as a Molecular Target, 2016
Table 13: Asthma Therapeutics Market, Global, Data for Antigen Presenting Glycoprotein CD1d as a Molecular Target, 2016
Table 14: Asthma Therapeutics Market, Global, Data for Interleukin 4 Receptor Subunit Alpha as a Molecular Target, 2016

List of Figures

Figure 1: Overall Pharmaceutical Industry, Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Products Approvals (%), 1987-2014
Figure 2: Overall Pharmaceutical Industry, First-in-Class and Non-First-in-Class Products, Sales Performance After Marketing Approval, 2006-2013 ($m)
Figure 3: Asthma Therapeutics Market, Global, Marketed Product Overview, 2016
Figure 4: Pharmaceutical Market, Global, Developmental Pipeline Overview, 2016
Figure 5: Asthma Therapeutics Market, Global, Pipeline by Stage of Development and Molecule Type, 2016
Figure 6: Asthma Therapeutics Market, Global, Pipeline by Molecular Target and Cytokine/Cytokine Receptor Subcategory, 2016
Figure 7: Asthma Therapeutics Market, Global, Pipeline by Molecular Target Subcategories, 2016
Figure 8: Asthma Therapeutics Market, Global, Molecular Target Category Comparison, Pipeline and Marketed Products, 2016
Figure 9: Asthma Therapeutics Market, Global, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets, 2016
Figure 10: Asthma Therapeutics Market, Global, Percentage of First-in-Class Products in Pipeline by Stage of Development (%), 2016
Figure 11: Asthma Therapeutics Market, Global, Percentage of First-in-Class Products in Pipeline by Molecular Target Family (%), 2016
Figure 12: Asthma Therapeutics Market, Global, First-in-Class Molecular Targets in Pipeline Development, 2016
Figure 13: Asthma Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix, 2016
Figure 14: Asthma Therapeutics Market, Global, Pipeline Programs Targeting Calcium Release Activated Calcium Channel Protein 1, 2016
Figure 15: Asthma Therapeutics Market, Global, Pipeline Programs Targeting CXC Chemokine Receptors, 2016
Figure 16: Asthma Therapeutics Market, Global, Pipeline Programs Targeting Spleen Tyrosine Kinase, 2016
Figure 17: Asthma Therapeutics Market, Global, Pipeline Programs Targeting Compliment Component 5a Receptor 1, 2016
Figure 18: Asthma Therapeutics Market, Global, Pipeline Programs Targeting Interleukin-33, 2016
Figure 19: Asthma Therapeutics Market, Global, Pipeline Programs Targeting CC Chemokine Receptor Type-3, 2016
Figure 20: Asthma Therapeutics Market, Global, Pipeline Programs Targeting Antigen Presenting Glycoprotein CD1d, 2016
Figure 21: Asthma Therapeutics Market, Global, Pipeline Programs Targeting Interleukin 4 Receptor Subunit Alpha, 2016
Figure 22: Pharmaceutical Market, Global, Industry-Wide Deals by Stage of Development, 2006-2014
Figure 23: Pharmaceutical Market, Global, Industry Licensing Deal Values by Stage of Development, 2006-2014
Figure 24: Asthma Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2016
Figure 25: Asthma Therapeutics Market, Global, Licensing Deals by Stage of Development, 2006-2016
Figure 26: Asthma Therapeutics Market, Global, Licensing Deals by Molecule Type, 2006-2016
Figure 27: Asthma Therapeutics Market, Global, Licensing Deals by Molecular Target, 2006-2016
Figure 28: Asthma Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2016
Figure 29: Asthma Therapeutics Market, Global, Co-Development Deals by Region and Value, 2006-2016
Figure 30: Asthma Therapeutics Market, Global, Co-Development Deals by Stage of Development, 2006-2016
Figure 31: Asthma Therapeutics Market, Global, Co-Development Deals by Molecule Type, 2006-2016
Figure 32: Asthma Therapeutics Market, Global, Co-Development Deals by Molecular Target, 2006-2016
Figure 33: Asthma Therapeutics Market, Global, Co-Development Deals Valued Above $100m, 2006-2016
Figure 34: Asthma Therapeutics Market, Global, First-in-class Programs in Active Development Involved in Previous Deals, 2016
Figure 35: Asthma Therapeutics Market, Global, First-in-class Programs in Active Development Without Recorded Prior Deal Involvement, 2016

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll